VY-3-135 is an orally active, stable and specific acetyl-CoA synthetase 2 (ACSS2) inhibitor with IC50 of 44 nM, showing no inhibitory activity against recombinant human ACSS1 or ACSS3. VY-3-135 can effectively inhibit ACSS2-dependent fatty acid metabolism but has no effect on gene expression in tumors.